UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms Controlling PD-L1 Expression in Cancer

Molecular cell, 2019-11, Vol.76 (3), p.359-370

2019

Volltextzugriff (PDF)

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

Cell research, 2018-08, Vol.28 (8), p.862-864

2018

Volltextzugriff (PDF)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

Nature communications, 2018-05, Vol.9 (1), p.1908-17, Article 1908

2018

Volltextzugriff (PDF)

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

The Journal of clinical investigation, 2021-04, Vol.131 (8), p.1-13

2021

Volltextzugriff (PDF)

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

Cell research, 2019-01, Vol.29 (1), p.83-86

2019

Volltextzugriff (PDF)

Deubiquitination and Stabilization of PD-L1 by CSN5

Cancer cell, 2016-12, Vol.30 (6), p.925-939

2016

Volltextzugriff (PDF)

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Molecular cell, 2018-08, Vol.71 (4), p.606-620.e7

2018

Volltextzugriff (PDF)

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

Cancer cell, 2018-02, Vol.33 (2), p.187-201.e10

2018

Volltextzugriff (PDF)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Nature communications, 2016-08, Vol.7 (1), p.12632-11, Article 12632

2016

Volltextzugriff (PDF)

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

The Journal of clinical investigation, 2019-08, Vol.129 (8), p.3324-3338

2019

Volltextzugriff (PDF)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Nature communications, 2019-11, Vol.10 (1), p.5114-5114, Article 5114

2019

Volltextzugriff (PDF)

Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity

Cancer research (Chicago, Ill.), 2020-06, Vol.80 (11), p.2298-2310

2020

Volltextzugriff (PDF)

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation

Nature communications, 2021-05, Vol.12 (1), p.2788-2788, Article 2788

2021

Volltextzugriff (PDF)

Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (14), p.3761-3768

2018

Volltextzugriff (PDF)

Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation

International journal of biological sciences, 2023-01, Vol.19 (10), p.2957-2973

2023

Volltextzugriff (PDF)

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity

International journal of biological sciences, 2023-01, Vol.19 (14), p.4644-4656

2023

Volltextzugriff (PDF)

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Nature communications, 2020-01, Vol.11 (1), p.673-673, Article 673

2020

Volltextzugriff (PDF)

Thymosin Beta-4 Knockdown in IEC-6 Normal Intestinal Epithelial Cells Induces DNA Re-replication Via Downregulating Emi1

Journal of cellular physiology, 2014-11, Vol.229 (11), p.1639-1646

2014

Volltextzugriff (PDF)

Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (11), p.2185-2195

2022

Volltextzugriff (PDF)

New Approaches on Cancer Immunotherapy

Cold Spring Harbor perspectives in medicine, 2020-08, Vol.10 (8), p.a036863

2020

Volltextzugriff (PDF)

Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma

Journal of hepatology, 2021-04, Vol.74 (4), p.907-918

2021

Volltextzugriff (PDF)

Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer

The Journal of biological chemistry, 2022-04, Vol.298 (4), p.101817-101817, Article 101817

2022

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(110)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Mechanisms Controlling PD-L1 Expression in Cancer

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

Deubiquitination and Stabilization of PD-L1 by CSN5

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation

Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression

Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Thymosin Beta-4 Knockdown in IEC-6 Normal Intestinal Epithelial Cells Induces DNA Re-replication Via Downregulating Emi1

Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function

New Approaches on Cancer Immunotherapy

592 ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma

Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

Suchergebnisse filtern